Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (647)	4/7/2005 2:15:30 PM
From: Icebrg	Respond to of 946

Canfield has now filed a form 4, reporting that he has reduced his holding in CTIC with 116.667 shares. Price achieved 0 USD. After this transaction he still holds 39.499 shares. Canfield was the Chief Administrative Officer, who left the company a couple of days ago, not to be replaced. The majority of the shares lost (100.000) were granted a little bit more than a month ago, when CTIC's management attempted to enrich themselves in expectation of good results in the pivotal Xyotax trials. Evidently Canfield had to return the whole lot plus some more. Erik